Healthcare [ 11/13 ] | Biotechnology [ 94/159 ]
NASDAQ | Common Stock
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases.
The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia.
It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma.
The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | 0 Increased by +100% | -0.14 Increased by +100% |
| Mar 27, 24 | -0.04 Increased by +86.67% | -0.15 Increased by +73.33% |
| Nov 14, 23 | -0.01 Increased by +96.55% | -0.17 Increased by +94.12% |
| Aug 14, 23 | -0.31 Increased by 0% | -0.19 Decreased by -63.16% |
| May 15, 23 | -0.27 Increased by +20.59% | -0.27 |
| Mar 27, 23 | -0.3 Increased by +42.31% | -0.25 Decreased by -20% |
| Nov 14, 22 | -0.29 Increased by +12.12% | -0.31 Increased by +6.45% |
| Aug 15, 22 | -0.31 Increased by +13.89% | -0.29 Decreased by -6.9% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 1.11 M Increased by +N/A% | -8.84 M Increased by +79.61% | Decreased by -795.77% Decreased by N/A% |
| Sep 30, 23 | 673 K Increased by +N/A% | -1.52 M Increased by +91.81% | Decreased by -225.71% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -31.68 M Increased by +13.45% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -22.34 M Decreased by -5.76% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -43.36 M Decreased by -40.64% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -18.54 M Increased by +5.56% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -36.6 M Decreased by -71.9% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -21.12 M Decreased by -17.1% | Decreased by N/A% Decreased by N/A% |